ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1673

Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States
Abstract Number: 1334

Assessing the Performance of Validated Frailty Instruments in Veterans with Rheumatoid Arthritis (RA)
Abstract Number: 1875

Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Abstract Number: 1076

Assessing the Reliability of ChatGPT on Recombinant Zoster Vaccination for Patients with Rheumatic and Musculoskeletal Diseases
Abstract Number: 1301

Assessment and Comparison of Long-term Skill Retention Following a Teledidactic Musculoskeletal Ultrasound Course for Medical Students– the TELMUS Follow-up Study
Abstract Number: 2281

Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Abstract Number: 0850

Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis
Abstract Number: 0976

Assessment of Current Trends in Demographic and Clinical Characteristics of Male Patients with Rheumatoid Arthritis in North India
Abstract Number: 0395

Assessment of Enthesitis by Pediatric Rheumatology Providers
Abstract Number: 2249

Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
Abstract Number: 1297

Assessment of Knowledge of Osteoporosis Among Female Nursing Students and Staff Nurses in an Urban Medical College in India
Abstract Number: 2361

Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
Abstract Number: 1028

Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Abstract Number: 0293

Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Abstract Number: 2684

Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].